People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye co ...

The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The Medicines and Healthcare products Regulatory Agency issued an alert as a crackdown on prescriptions was underway ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed the toll up to the end of January with 82 people ...